Onconetix, Inc.
NASDAQ: ONCO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David Allan White
- Employees
- 12
- Headquarters
- Cincinnati, United States
- IPO year
- 2022
- Market cap
- $334.0K
- Website
- https://onconetix.gcs-web.com
Loading ONCO…
Loading profile data…Frequently asked questions about ONCO
What does Onconetix, Inc. (ONCO) do?
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to mana...
Where does ONCO trade?
Onconetix, Inc. (ONCO) trades on the NASDAQ Capital Market.
What sector is ONCO in?
Onconetix, Inc. (ONCO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Onconetix, Inc.?
David Allan White is the chief executive officer of Onconetix, Inc. (ONCO).
Where is Onconetix, Inc. headquartered?
Onconetix, Inc. is headquartered in United States.
Does ONCO pay a dividend?
Onconetix, Inc. (ONCO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ONCO go public?
Onconetix, Inc. (ONCO) completed its initial public offering in 2022.